CG
ACAD icon

Cutler Group’s Acadia Pharmaceuticals ACAD Stock Holding History

Cutler Group’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,500
Closed -$1K – 4284
2022
Q3 		$1K Buy
+1,500
New +$24.3K ﹤0.01% 4392
2022
Q2 		– Sell
-3,900
Closed -$7K – 4869
2022
Q1 		$7K Buy
3,900
+1,600
+70% +$38.7K ﹤0.01% 3844
2021
Q4 		$4K Buy
+2,300
New +$46.3K ﹤0.01% 4279
2021
Q2 		– Sell
-20,000
Closed -$9K – 5572
2021
Q1 		$9K Buy
+20,000
New +$880K ﹤0.01% 3856
2019
Q4 		– Sell
-15,000
Closed -$25K – 3887
2019
Q3 		$25K Sell
15,000
-43,600
-74% -$1.32M ﹤0.01% 2011
2019
Q2 		$46K Buy
58,600
+36,100
+160% +$922K ﹤0.01% 1594
2019
Q1 		$49K Buy
22,500
+14,200
+171% +$332K 0.01% 1433
2018
Q4 		$53K Sell
8,300
-4,500
-35% -$87.4K 0.01% 1437
2018
Q3 		$42K Buy
12,800
+7,500
+142% +$118K ﹤0.01% 1712
2018
Q2 		$75K Sell
5,300
-59,500
-92% -$1.06M 0.01% 1340
2018
Q1 		$344K Buy
64,800
+29,600
+84% +$820K 0.03% 555
2017
Q4 		$134K Buy
35,200
+3,000
+9% +$95.9K 0.01% 1201
2017
Q3 		$74K Sell
32,200
-9,500
-23% -$309K ﹤0.01% 1906
2017
Q2 		$216K Sell
41,700
-45,700
-52% -$1.36M 0.01% 1211
2017
Q1 		$173K Sell
87,400
-9,300
-10% -$328K 0.01% 1294
2016
Q4 		$115K Sell
96,700
-7,600
-7% -$201K ﹤0.01% 1771
2016
Q3 		$250K Buy
104,300
+49,200
+89% +$1.67M 0.01% 1037
2016
Q2 		$76K Sell
55,100
-51,700
-48% -$1.73M ﹤0.01% 1945
2016
Q1 		$118K Buy
106,800
+93,400
+697% +$2.04M 0.01% 1458
2015
Q4 		$24K Buy
+13,400
New +$472K ﹤0.01% 3213

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AWA
Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Cutler Group's ACAD Position: Q3 2022 in Review

Cutler Group sold out of Acadia Pharmaceuticals (ACAD) in Q3 2022, closing a stake of 800 shares — an estimated $13K sold.

Cutler Group first reported a position in ACAD in Q4 2015 and held it in 21 quarters. The position peaked at $1.62M in Q1 2017. 222 funds tracked by Wall St. Rank hold ACAD as of Q3 2022.

  • Cutler Group reported no remaining Acadia Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Cutler Group sold 800 Acadia Pharmaceuticals shares in Q3 2022, an estimated $13K.
  • Cutler Group first reported a position in Acadia Pharmaceuticals in Q4 2015 and held it in 21 quarters.
  • Cutler Group's Acadia Pharmaceuticals position peaked at $1.62M in Q1 2017.
  • 222 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2022.

Based on Cutler Group's 13F filing for Q3 2022, filed 25 Oct 2022.